OBJECTIVES: To assess the extent of reporting of bone mineral density (BMD) measurements and pharmacologic treatment among women over age 50 with osteoporosis in a nationally-representative Electronic Medical Record (EMR) database. The diagnosis of osteoporosis is based on a history of a prior fragility fracture or a low BMD, defined as a T-score ≤ -2.5 on a dual energy x-ray absorptiometry (DEXA) test. DEXA is the standard measurement for bone density, which is usually calculated at the hip, and T-scores represent the number of standard deviations below (or above) the mean for young healthy women. Bisphosphonates are first-line pharmacologic therapy for both women and men with T-scores diagnostic of osteoporosis. METHODS: The EMR database reviewed was the Medical Quality Improvement Consortium (MQIC) database from GE. This database contains EMR data collected from over 11,000 ambulatory providers in the United States and includes over 12 million patients as of April, 2009. Records were reviewed for all women over age 50 for the presence of a BMD test result and bisphosphonate prescriptions. RESULTS: Of 2,382,357 women over age 50, only 16,550 had a BMD test documented in their medical records. Of these, 16,505 had a T-score